Immunotherapy and Personalized Treatments

So far, immunotherapy has been a game-changer in other cancers but not pancreatic cancer. Is that finally changing? In this episode of PancChat, host Alisyn Camerota sits down with Dr. Elizabeth Jaffee, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and chief medical advisor of the Lustgarten Foundation. Dr. Jaffee breaks down the science behind pancreatic cancer's resistance to immunotherapy, the promise of cancer vaccines, and the emergence of KRAS inhibitors as a new class of targeted therapies. After thirty years in the field, she shares why she is more optimistic than ever. PancChat is a collaboration between Let's Win Pancreatic Cancer and PanCAN.